Bristol Myers Squibb Company (NYSE:BMY) Stake Lifted by Aviance Capital Partners LLC

Aviance Capital Partners LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,704 shares of the biopharmaceutical company’s stock after buying an additional 686 shares during the quarter. Aviance Capital Partners LLC’s holdings in Bristol Myers Squibb were worth $2,239,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Moody Aldrich Partners LLC bought a new position in Bristol Myers Squibb during the 1st quarter worth $302,000. Aurora Private Wealth Inc. bought a new position in Bristol Myers Squibb during the 1st quarter worth $6,039,000. Davidson Trust Co. grew its stake in Bristol Myers Squibb by 10.1% during the 1st quarter. Davidson Trust Co. now owns 14,064 shares of the biopharmaceutical company’s stock worth $858,000 after buying an additional 1,285 shares during the last quarter. Checchi Capital Advisers LLC grew its stake in Bristol Myers Squibb by 8.9% during the 1st quarter. Checchi Capital Advisers LLC now owns 13,114 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 1,076 shares during the last quarter. Finally, North Capital Inc. bought a new position in shares of Bristol Myers Squibb in the first quarter worth $67,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BMY shares. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Finally, Argus raised Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $58.00.

Bristol Myers Squibb Trading Down 1.3%

Shares of NYSE BMY opened at $47.02 on Friday. Bristol Myers Squibb Company has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a market cap of $95.68 billion, a price-to-earnings ratio of 17.61, a P/E/G ratio of 1.41 and a beta of 0.36. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The business has a fifty day simple moving average of $47.75 and a 200-day simple moving average of $53.69.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the prior year, the business posted ($4.40) earnings per share. Bristol Myers Squibb’s revenue was down 5.6% compared to the same quarter last year. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.27%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is 92.88%.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is currently owned by corporate insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.